| [25] |
Henry D, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study [J]. Am J Hematol, 2022, 97(2): 174-184.
|
| [26] |
Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD Patients with anemia on hemodialysis in Japan [J]. J Am Soc Nephrol, 2020, 31(7): 1628-1639.
|
| [27] |
Fishbane S, El-Shahawy M, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study [J]. J Am Soc Nephrol, 2021, 32(3): 737-755.
|
| [28] |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 18(2): 271-280.
|
| [29] |
Wing P, Keeley T, Zhuang X, et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells [J]. Cell Rep, 2021, 35(3)：109020.
|
| [30] |
Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis [J]. N Engl J Med, 2019, 381(11): 1001-1010.
|
| [31] |
Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials [J]. Clin J Am Soc Nephrol, 2021, 16(8): 1190-1200.
|
| [32] |
Li ZL, Lv LL, Wang B, et al. The profibrotic effects of MK-8617 on tubulointerstitial fibrosis mediated by the KLF5 regulating pathway [J]. FASEB J, 2019, 33(11): 12630-12643.
|
| [33] |
Tokuyama A, Kadoya H, Obata A, et al. Roxadustat and thyroid-stimulating hormone suppression [J]. Clin Kidney J, 2021, 14(5): 1472-1474.
|
| [34] |
Luo W, Lin B, Wang Y, et al. PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility [J]. Mol Biol Cell, 2014, 25(18): 2788-2796.
|
| [35] |
Conza G, Cafarello S, Zheng X, et al. PHD2 targeting overcomes breast cancer cell death upon glucose starvation in a PP2A/B55α-mediated manner [J]. Cell Rep, 2017, 18(12): 2836-2844.
|
| [36] |
Li Z, Lv L, Tang T, et al. HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation [J]. Kidney Int, 2019, 95(2): 388-404.
|
| [1] |
Vanderhaeghen T, Vandewalle J, Libert C. Hypoxia-inducible factors in metabolic reprogramming during sepsis [J]. FEBS J, 2020, 287(8): 1478-1495.
|
| [2] |
Scholz C, Cavadas M, Tambuwala M, et al. Regulation of IL-1beta-induced NF-kappaB by hydroxylases links key hypoxic and inflammatory signaling pathways [J]. Proc Natl Acad Sci USA, 2013, 110(46): 18490-18495.
|
| [3] |
Taylor C, Doherty G, Fallon P, et al. Hypoxia-dependent regulation of inflammatory pathways in immune cells [J]. J Clin Invest, 2016, 126(10): 3716-3724.
|
| [4] |
Kobayashi H, Gilbert V, Liu Q, et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury [J]. J Immunol, 2012, 188(10): 5106-5115.
|
| [5] |
Yeh T, Leissing T, Abboud M, et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials [J]. Chem Sci, 2017, 8(11): 7651-7668.
|
| [6] |
Soilleux E, Turley H, Tian YM, et al. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues [J]. Histopathology, 2005, 47(6): 602-610.
|
| [7] |
Chan M, Atasoylu O, Hodson E, et al. Potent and selective triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases with activity in the murine brain [J]. PLoS One, 2015, 10(7): e0132004.
|
| [8] |
Price C, Gill S, Ho ZV, et al. Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers [J]. Cancer Res, 2019, 79(10): 2564-2579.
|
| [9] |
Xie R, Fang X, Zheng X, et al. Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation [J]. Biomed Pharmacother, 2019, 118: 109175.
|
| [10] |
Miao AF, Liang JX, Yao L, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation [J]. Ren Fail, 2021, 43(1): 803-810.
|
| [11] |
Han F, Wu G, Han S, et al. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury [J]. Respir Physiol Neurobiol, 2020, 281: 103506.
|
| [12] |
Yang DG, Gao YY, Yin ZQ, et al. Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway [J]. Acta Pharmacol Sin, 2023, 44(2): 308-320.
|
| [13] |
Eleftheriadis1 T, Pissas1 G, Mavropoulos A, et al. In mixed lymphocyte reaction, the hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat suppresses cellular and humoral alloimmunity [J]. Arch Immunol Ther Exp, 2020, 68(6): 31.
|
| [14] |
Yang Y, Yu X, Zhang Y, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury [J]. Clin Sci (Lond), 2018, 132(7): 825-838.
|
| [15] |
Li X, Zou Y, Xing J, et al. Pretreatment with roxadustat (FG-4592) attenuates folic acid-induced kidney injury through antiferroptosis via Akt/GSK-3beta/Nrf2 pathway [J]. Oxid Med Cell Longev, 2020, 2020: 6286984.
|
| [16] |
Schley G, Klanke B, Kalucka J, et al. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis [J]. Kidney Int, 2019, 96(2): 378-396.
|
| [17] |
Gao Y, Jiang X, Yang D, et al. Roxadustat, a hypoxia-inducible factor 1α activator, attenuates both long- and short-term alcohol-induced alcoholic liver disease [J]. Front Pharmacol, 2022, 13: 895710.
|
| [18] |
Yoshida T, Okumura T, Matsuo Y, et al. Activation of transcription factor HIF inhibits IL-1β-induced NO production in primary cultured rat hepatocytes [J]. Nitric Oxide, 2022, 124: 1-14.
|
| [19] |
Chen N, Hao C, Liu B, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis [J]. N Engl J Med, 2019, 381(11): 1011-1022.
|
| [20] |
Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients [J]. J Am Soc Nephrol, 2016, 27(4): 1225-1233.
|
| [21] |
Provenzano R, Besarab A, Sun C, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD [J]. Clin J Am Soc Nephrol, 2016, 11(6): 982-991.
|
| [22] |
Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study [J]. Am J Kidney Dis, 2016, 67(6): 912-924.
|
| [23] |
陈豫闽，刘俊英，贾国强，等. 罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果[J]. 广东医学，2021, 2(5): 216-220.
|
| [24] |
孙艳玲，谢华，康喆，等. 罗沙司他治疗初始血液透析患者肾性贫血20例疗效研究 [J]. 中国实用内科杂志，2020, 11(5): 942-946.
|